Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
04:01pm, Thursday, 08'th Aug 2024
Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $
Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Thursday, 01'st Aug 2024
Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10 Best Small and Mid-Cap Stocks to Consider Buying in August
06:30am, Thursday, 01'st Aug 2024
Big tech stocks cooled off in July, while smaller growth companies rallied. An anticipated rate cut could amplify this trend reversal in August and beyond.
Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?
05:31am, Wednesday, 31'st Jul 2024
An analyst from Piper Sandler recently downgraded Iovance Biotherapeutics and lowered the firm's price target on the stock The FDA approved Iovance's first drug in February, and investors still aren't
Why Iovance Biotherapeutics Stock Stumbled Today
06:24pm, Monday, 29'th Jul 2024
An analyst downgraded his recommendation on the biotech. In spite of that, these are exciting times for Iovance.
SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf
Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy
01:55pm, Monday, 29'th Jul 2024
Piper Sandler downgraded Iovance Biotherapeutics Inc IOVA, citing the slow launch of Amtagvi (lifileucel), a prescription medicine used to treat adults with a type of skin cancer that cannot be remove
Life May Soon Get Easier for (Some) Biotech Stocks. Here's Why.
09:37am, Monday, 29'th Jul 2024
The cost of taking out fresh debt is an important consideration for some biotechs. There's reason to believe that debt financing is about to get a bit cheaper.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:00pm, Friday, 19'th Jul 2024
SAN CARLOS, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:50am, Thursday, 18'th Jul 2024
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
7 ‘Death Cross' Stocks That Could Be Contrarian Buys
02:29pm, Wednesday, 17'th Jul 2024
Death cross stocks – on the surface, the title sounds incredibly menacing. However, it may be one of the more misunderstood concepts.
Is Iovance Biotherapeutics a Millionaire Maker?
05:45am, Sunday, 14'th Jul 2024
Iovance Biotherapeutics just launched its first therapy. Its revenue is likely to start ramping up.
3 Under-$10 Biotech Stocks That Could Make You Rich
02:23pm, Thursday, 11'th Jul 2024
Low-cap biotech companies are a high-risk but high-reward investment choice. If their clinical trials are successful, that can often mean an explosion in value as investors anticipate a buyout.
First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Cal
Is It Too Late to Buy Iovance Biotherapeutics Stock?
04:05am, Friday, 28'th Jun 2024
Iovance's shares took off earlier this year after its cell therapy obtained accelerated approval. The company, however, still remains deeply unprofitable and is burning through cash at a high rate.
